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PIN10
COST-UTILITY OF SELECTIVE BUPRENORPHINE
SUBSTITUTION FOR METHADONE
MAINTENANCE IN PREVENTING HIV
TRANSMISSION
Wall MJ1, Pollack HA2
1University of Michigan and Pﬁzer Inc, Ann Arbor, MI, USA;
2University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: Injection drug users comprise more than
35% of new HIV cases, while an estimated 69.1% of
patients currently enrolled in methadone maintenance
programs (MMT) receive sub-optimal dosages (<80mg/
day). Buprenorphine (BPN) has been suggested as an
alternative to methadone due to less adverse effects and
lower abuse potential. However, BPN has not consistently
outperformed optimal dose MMT. The objective is to
compare the cost-utility of selective BPN substitution into
current practice MMT, with emphasis on its role in HIV
infection. We also explore the cost-utility of increasing
minimum methadone dosage from current practice.
METHODS: We employed a dynamic epidemic (Markov)
model to measure the effects of substituting BPN for 
sub-optimal methadone dosing (SubMT) (<60mg or 
<80mg/d) on health care costs and quality-adjusted life-
years (QALYs) of intravenous heroin users. Analyses were
performed with HIV prevalence of 5% or 40% within the
population, considering a cost of $5 per day for BPN
therapy. Figures are calculated using a 100-year time
horizon, calculating present discounted values for both
health care costs and QALYs.
RESULTS: Substitution of BPN for SubMT <60mg, and
<80mg, per day result in a cost per additional QALY of
$5,580–$14,790, and $18,957–$59,431, respectively.
Increasing the minimum dose of therapy to 80mg per day
dominates all alternative treatment regimes, though
increasing minimum doses to 60mg is also superior to
current practice. BPN is dominant over increasing
minimum methadone doses to 60mg, but not to 80mg,
if BPN increases quality of life by 1% over MMT through
reduced adverse effects.
CONCLUSIONS: Selective substitution of BPN for
methadone is cost-effective for daily methadone doses
below 60mg, and may be cost-effective for all doses
below 80mg depending on side-effect proﬁle and HIV
prevalence. BPN provides a useful additional treatment
approach, though BPN appears less cost-effective than
optimal-dose methadone therapy.
PIN11
INITIAL ANTIMICROBIAL THERAPY AND
OUTCOMES IN PATIENTS HOSPITALIZED WITH
COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Onesirosan PT, Gutierrez B, Gaylord-Miles B, Hatch V
Premier, Inc, Charlotte, NC, USA
OBJECTIVES: Wide variations in antimicrobial manage-
ment of CAP have been reported despite the existence of
guidelines. The objective of this analysis was to assess the
association between initial antimicrobial therapy and out-
comes (therapy duration, total antimicrobial cost, length
of stay and total hospital cost) in two subpopulations of
hospitalized adults with ICD-9 codes for CAP: ICU and
non-ICU.
METHODS: The antimicrobial regimen received within
the ﬁrst 72 hours was determined for CAP patients from
188 facilities between January and December 2000.
RESULTS: Among ICU patients, initial therapy with a
ﬂuoroquinolone alone was associated with the best out-
comes, followed by a ﬂuoroquinolone plus a 3rd genera-
tion cephalosporin, a macrolide plus a 3rd generation
cephalosporin, a beta-lactam/beta-lactamase inhibitor
alone, and other regimens. This ranking was consistent
across all levels of pneumonia severity. Of the 12 initial
therapy regimens identiﬁed among non-ICU patients, a
macrolide alone gave the best outcome, followed by a 
ﬂuoroquinolone alone, a 2nd generation cephalosporin
plus a macrolide, and a 2nd generation cephalosporin
alone. The worst outcomes were associated with a ﬂuo-
roquinolone plus a penicillin, followed by a ﬂuoro-
quinolone plus other cephalosporin. This ranking was
also consistent across all levels of pneumonia severity.
Fifty-nine percent of the initial therapy regimens for non-
ICU patients were consistent with the Infectious Diseases
Society of America’s guidelines (1998) compared with
only 22% for ICU patients.
CONCLUSIONS: Initial therapy with a ﬂuoroquinolone
alone, a regimen inconsistent with the IDSA guidelines,
gave the best outcomes for CAP patients in the ICU while
a macrolide alone (guideline-consistent) was associated
with the best outcomes for non-ICU patients.
PIN12
COSTS OF TREATMENT FOR AMBULATORY
LOWER RESPIRATORY TRACT INFECTION IN
QUEBEC SENIORS
Kennedy WA, Laurier C, Paré M, Philibert L
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Evaluate costs of ambulatory treatment of
lower respiratory tract infection (LRTI) in seniors.
METHODS: Using claims data from Quebec public
provincial health programs for physician services and 
prescriptions dispensed, we drew a sample of seniors
diagnosed with LRTI in an ambulatory setting subse-
quently receiving an antibiotic from a community phar-
macy. Failure of antibiotic was deﬁned as receipt of a
second antibiotic or inpatient physician visit with LRTI
diagnosis within a 15-day window following antibiotic
receipt. Costs of treatment (CDN$) were those associated
with treatment episode and included medical visits,
antibiotics, and hospitalisations associated with LRTI
diagnosis. Treatment episode started with the initial visit
and terminated 15 days after end of recorded duration of
antibiotic received, extended by treatment duration (plus
15 days) of any additional antibiotics received during this
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period. The episode ended if an inpatient visit was
recorded. Hospitalisation costs were estimated according
to age-group CMG-speciﬁc resource intensity weights.
RESULTS: Of 10,565 subjects, 10.1% were deemed to 
be treatment failure. For subjects without failure, mean
treatment cost was $69.95 (SD = 20.70) compared with
$515.81 (SD = 911.03). The results of multiple regression
on log-transformed total costs using as independent vari-
ables the type of antibiotic initially prescribed, age group,
gender, diagnosis and chronic disease score, suggest that
age 75+, diagnosis of pneumonia (contrasted to bron-
chitis), and a chronic disease score of 4+ are associated
with increased total cost. Use of cephalosporins, 
clarithromycin 500 and quinolones were associated with
higher total cost than use of azithromycin 250mg. Use 
of clarithromycin 250, erythromycin, amoxicillin, other
penicillins, trimethoprim-sulfas and other antibiotics
were associated with lower total cost than use of
azithromycin 250mg.
CONCLUSIONS: Total cost of treatment of LRTI in
seniors is associated with older age, high disease score,
and type of antibiotic used.
PIN13
THE IMPACT OF ANTIBIOTIC SELECTION ON
TREATMENT OUTCOMES FOR ACUTE 
OTITIS MEDIA
Ayyar Krishnan A, Christensen DB
University of North Carolina, Chapel Hill, NC, USA
Acute Otitis Media (AOM) is the most common medical
condition in children and results in 30 million physician
visits annually. Clinical practice guidelines call for use 
of well-established ﬁrst-line antibiotics for treatment in
spite of the introduction of several newer second-line
antibiotics.
OBJECTIVE: This study sought to determine the impact
of antibiotic prescribing at initial visit on the probability
and frequency of AOM-related return visits among North
Carolina Medicaid patients.
METHODS: We identiﬁed new episodes of AOM among
continuously eligible patients below age 7 over a 1-year
period ending August 2000. We matched prescriptions
dispensed up to 3 days after the medical visit and we clas-
siﬁed patients as having received ﬁrst-line or second-line
antibiotic, based on CDC practice guidelines. We identi-
ﬁed return visits as those occurring within 30 days of the
index visit. Using a two-part model we estimated two
equations that modeled, ﬁrst, the probability of a return
visit and second, the log-transformed frequency of return
visits among patients with a return visit, adjusting for
clustering of errors at the provider level. Independent
variables included treatment group, patient demograph-
ics, physician specialty, practice site, and seasonality.
RESULTS: A total of 52,556 recipients received an 
antibiotic prescription at an AOM-related index visit 
from 1,617 providers, 66% of whom were pediatricians.
First-line antibiotics accounted for 65% of antibiotics
prescribed at index visit. The average annual antibiotic
expenditure for patients dispensed ﬁrst-line antibiotics at
index visit was $12 and $42 for patients receiving second-
line antibiotics. Patients receiving ﬁrst-line antibiotics had
a lower probability of (OR = 0.78, 95% CI [0.74, 0.82])
and fewer return visits (3%, p-value <0.001), as com-
pared to patients receiving second-line antibiotics.
CONCLUSIONS: First-line antibiotics were associated
with a lower probability and frequency of return visits as
compared to second-line antibiotics. However, only 65%
of initial visits resulted in a prescription for a ﬁrst-line
antibiotics. Given the better treatment outcomes and
lower costs, considerable cost-saving potential exists if
physicians were encouraged to prescribe ﬁrst-line antibi-
otics more often for initial AOM visits.
PIN14
HEALTH RESOURCE UTILIZATION IN THE
TREATMENT OF ACUTE BACTERIAL SINUSITIS
Ahn J1, Mullins CD1, Shaya FT1, Merchant S2, Corcoran G2,
Church D2
1University of Maryland, Baltimore, MD, USA; 2Bayer
Pharmaceutical Corporation, West Haven, CT, USA
OBJECTIVE: To estimate the burden of illness of Acute
Bacterial Sinusitis (ABS) to health care providers. 
Background: ABS is a common secondary infection, with
roughly 20 million cases annually in the US. Thus, the
treatment of ABS is associated with signiﬁcant health
resource utilizations.
METHODS: Using clinical trial data of drug therapies 
for ABS, the health resource utilization patterns such 
as Medical Doctor (MD) time, Registered Nurse and
Physician Assistant (RN&PA) time, and Ofﬁce Staff time
(OS) spent on treatment-related call backs for the 10 day
follow-up period, are examined by the economic value of
this time is measured based on nationally reported wage
rates for each category.
RESULTS: Of 792 patients that were valid for efﬁcacy,
the demographic information from the data shows mean
age of 44.26 (SD 15.45), 64% female, 94% Caucasians,
and 5% African Americans. Twenty-one percent of the
patients called back in the 10-day follow-up period. For
these patients with call back, 8.91 minutes (SD 7.37) was
for MD time, 6.59 minutes (SD 8.85) of RN&PA time,
and 4.24 minutes (SD 5.55) of OS time were recorded on
average. Including the other 79% of patients who did not
call back, the average time spent on the sum of all three
categories was 4.11 minutes (SD 11.59). These numbers
can be translated into the average follow-up wage cost
for health care professions of $2.15 (SD 5.75) per person
with ABS. For 20 million cases, this number implies $43
million total wage cost for the health care side. 
CONCLUSION: ABS is so common that it causes a 
signiﬁcant burden in terms of health care resource 
utilization. The burden is signiﬁcant not only in terms of
the initial physician visit, but also in terms of follow up
visits and call-backs.
